设计一项多中心、随机、双盲、安慰剂对照的III期试验:评估九价人乳头瘤病毒(HPV)疫苗预防HIV感染男性持续性口腔HPV感染——ULACNet试验201
本文描述首项在HIV感染男性中评估九价HPV疫苗预防持续性口腔HPV感染的随机(1:1)、双盲、安慰剂对照III期试验的原理、设计与人群特征。主要目的是证明3剂方案(第1天、第2、6个月)相比安慰剂可降低入组时口腔HPV阴性男性中疫苗型别持续性(≥6个月)口腔HPV感染的发生率。试验2021年2月开始,2024年2月在巴西、墨西哥和波多黎各完成700名男性入组。
要点
- 首项在HIV感染男性中评估九价HPV疫苗预防持续性口腔HPV感染的随机双盲安慰剂对照III期试验。
- 主要目的为证明3剂方案较安慰剂降低疫苗型别持续性(≥6个月)口腔HPV感染发生率。
- 2021年2月启动,2024年2月在巴西、墨西哥和波多黎各完成700名男性入组。
核心结论
- 该试验旨在评估九价HPV疫苗在HIV感染男性中预防持续性口腔HPV感染的有效性和免疫原性。
- 研究结果可能为HIV感染者的疫苗接种策略提供政策参考。
研究设计与样本
- 多中心、随机(1:1)、双盲、安慰剂对照III期试验。
- 研究对象为20-50岁HIV感染男性,入组时对相关HPV型别口腔HPV阴性。
- 试验在巴西、墨西哥和波多黎各的临床中心开展,2021年2月开始,2024年2月完成700名男性入组。
- 九价HPV疫苗按3剂方案接种(第1天、第2个月和第6个月)。
- 主要目的为证明九价HPV疫苗相比安慰剂降低疫苗型别(6、11、16、18、31、33、45、52、58)持续性(≥6个月)口腔HPV感染的发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increased significantly among men, especially among men living with HIV. HPV vaccines have proven efficacy in preventing persistent anogenital HPV infections. However, less is known regarding vaccine efficacy against persistent oral HPV infection, the obligate precursor of OPSCC. In 2020, the 9-valent HPV (9vHPV) vaccine received accelerated approval from the FDA for the indication of prevention of HPV-related OPSCC and other head and neck cancers, pending confirmation of clinical benefit in further trials. Currently a Phase III trial is ongoing to evaluate efficacy of the 9vHPV vaccine in preventing persistent oral HPV infection in immunocompetent men (NCT04199689); however, no trials have been conducted in people living with HIV. Here we describe the rationale, design, and study population characteristics of the first randomized (1:1), double-blind, placebo-controlled trial evaluating the efficacy and immunogenicity of the 9vHPV vaccine in preventing persistent oral HPV infection in men aged 20-50 living with HIV. The primary objective is to demonstrate that the 9vHPV vaccine when given in a 3-dose regimen (Day 1, Months 2 and 6) reduces the incidence of persistent (≥6 months) oral HPV infection with 9vHPV vaccine types 6, 11, 16, 18, 31, 33, 45, 52, and 58 in men living with HIV who are oral HPV negative to the relevant HPV type at enrollment, compared with placebo. The trial began in February 2021 and completed enrollment of 700 men at clinical sites in Brazil, Mexico, and Puerto Rico in February 2024. The secondary objectives are to evaluate the vaccine-induced serum anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 responses, and the safety and tolerability of the 9vHPV vaccine in men living with HIV. Results from this study may inform policy regarding vaccination strategies for people living with HIV. ClinicalTrials.gov Identifier: NCT04255849.
引用
- Giuliano AR, Beltrame A, Villa LL, et al. Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201. Vaccine. 2025. PMID: 40609265. doi:10.1016/j.vaccine.2025.127447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。